Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY23 results · Jan–Mar 2023
Sun Pharma Advanced Research Company reported revenue from operations of ₹47.69 crore (up 88.9% from Q4 FY22) and net loss of ₹81.99 crore for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 47.69 | 25.24 | +88.9% | 131.09 | −63.6% |
| Other income | 10.73 | 0.22 | 49x | 0.03 | 358x |
| Total income | 58.42 | 25.46 | +129.5% | 131.12 | −55.4% |
| Profit before tax | (81.99) | (71.05) | Loss widened | 10.15 | Turned loss |
| Net profit for the period | (81.99) | (71.05) | Loss widened | 10.15 | Turned loss |
| EPS, basic (₹) | (2.55) | (2.69) | not comparable | 0.37 | not comparable |
| Net margin (%) | -171.9 | -281.5 | 7.7 |
Standalone
- Filed with BSE
- 22 May 2023, 20:21 IST
- Board meeting
- 22 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE